↑  Read the latest from the desks  ·  fresh intelligence, published daily✦Quiet reading✦No ads, ever

✦Corporate brand & media services✦Made in Virginia Beach since 1997✦

Quest Diagnostics: Sound ship (one warning sign)Sound ship

Quest Diagnostics $DGX

Grew revenue 11.8% in FY2025 to $11.0 billion, operating margin 14.1% against a -12.4% median for medical laboratories, equity 44.2% of assets, and dividend per share up 7 years running.

Last filing10-Q, 23 Oct 2026

Next year, 80%$10.3B–$12.9B
Growth, on the year11.8%
Operating margin14.1%
Equity of assets44.2%
Credibility50%
Track record11 of 15
Your call, sealedNext year’s revenue, your range. Sealed now, graded when the annual report lands.
Edgarette’s full reading · exposure, experience, soundness, credibility, range

🫧 Edgar looked up Quest Diagnostics Inc ($DGX). Last filing: 10-Q, 2026-10-23. 11 event filings (8-K) in the past twelve months.

🔖 Exposure: revenue $11.0B (FY2025), total debt $5.7B. Experience: revenue up 11.8% on the year, up 0.6% a year over 4 years; operating margin 14.1%, up from 13.6%. Soundness: equity 44.2% of assets, return on equity 14.6%, payout 33.7% of profit, dividend per share up 7 years running. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $10.3B and $12.9B next year (method v4.1: its own 4-year record of growth weighed at 50% against $10B+ filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $9.3B to $14.1B. A statistical range, not company guidance. Against peers (17 filers, $50M+ revenue, services-medical laboratories): operating margin 14.1% against a -12.4% median; growth 11.8% against 13.8%.

Read from its own SEC filings · nothing written, nothing inferred

Quest Diagnostics Inc against its own record and its peers
Operating marginPeer median -12.4%14.1%Revenue, on the yearPeer median 13.8%11.8%Equity of assetsPeer median 65.3%44.2%Return on equityPeer median -7.0%14.6%Payout of profit33.7%Gold tick: the median of 15–17 peers with $50M+ revenue in services-medical laboratories
Handed back now, or kept to compound · of each dollar of profit
33.7% paid out66.3% keptHanded back per share$1.8up 7 years runningGrowth its own profit can fund9.7%managed 11.8% last year

Gold paid out, navy kept. Kept share × return on equity = the growth it can fund itself. Facts from the filings, not a recommendation.

Speed and cash · fiscal 2025

Cash Compass🌊 In between · no clear cash pattern yet
Inside viewTurns 17.1% of revenue into operating cash; revenue growing 3.7% a year over three years; pays and raised its dividend.
Outside viewAmong $10B+ companies: 59th percentile for cash, 46th for growth. cash growth

Both views must agree for a label · a description, not advice.

Cash flow (op · inv · fin · free)$1.9B · −$631M · −$1.4B · $1.4B
Investment book (cash · short · long)$420M · — · — · current ratio 1.04
Revenue swing · equity of assets9.8% · 44.2%

Quest Diagnostics is growing slower than its size class, with revenue that swings more. Its own audited SEC figures.

The figures, as filed

Fiscal year end2025-12-31
Revenue$11.0B
Revenue, on the year11.8%
Revenue, a year over the record0.6%
Operating margin14.1%
Operating margin, prior year13.6%
Net margin9.5%
Research and developmentnot filed separately
Total debt$5.7B
Equity of assets44.2%
Return on equity14.6%
Payout of profit33.7%
Dividend per share$1.8 · up 7 years running
Earnings per share$8.87
Book value per share$63.45
Revenue per share$97.65
Shares outstanding113,000,000
Audited years read5

Peers: the median of 17 filers with $50M+ revenue in services-medical laboratories.

Classic signals · fiscal 2025Altman Z″ 3.52 safe zone 1968Piotroski F 8 of 9 strong 2000Beneish M -2.65 below the −1.78 line 1999Sloan accruals -5.2% earnings backed by cash 1996DuPont ROE 15% = margin 9.5% × turns 0.68 × leverage 2.32

What a terminal subscription used to buy, a filing and arithmetic now give anyone. Published method, from the same filings. Display only: nothing here moves the range or its receipt. Why? →

Health HarborQuest Diagnostics sails as Sound ship1 warning sign

Health watch · 12 monthsDirector or officer change ×2

Versus peersoperating margin 14.1% vs a −12.4% median · revenue growth 11.8% vs 13.8% · cash beats 59% of its size class · growth beats 46% 17 services-medical laboratories filers

Trend · last year to this▲operating margin 13.6% → 14.1% · ▲revenue $9.9B → $11.0B · 5-year revenue: $10.8B · $9.9B · $9.3B · $9.9B · $11.0B

See all 9 services-medical laboratories companies on POPS4 sorted from the newest ship to the boat at the dock
#CompanyConditionOperating marginRevenue growthSales
1New shipVeracyteVCYTNew ship11.2%16.0%$517.1M
2New shipLabcorp HoldingsLHNew ship9.9%7.2%$14.0B
3New shipRadnetRDNTNew ship3.0%11.5%$2.0B
4Sound shipQuest DiagnosticsDGX · this companySound ship14.1%11.8%$11.0B
5Sound shipFortrea HoldingsFTRESound ship−32.0%1.0%$2.7B
6Old boatGuardant HealthGHOld boat−44.5%32.9%$982.0M
7Old boatLudwig Enterprises1960262Old boat−598243.8%—$0.0M
8Rotting at the dockBiodesixBDSXRotting at the dock−31.5%24.1%$88.5M
9Rotting at the dockBioNexus Gene LabBGLCRotting at the dock−39.9%−21.9%$7.4M

From each company’s own POPS4 card. Green beats the industry median above, red trails it. Not a rating and not investment advice.

Sailing speed follows growth: 3.7% a year crosses the harbor in 69 seconds.

🌊 Visit the Bay →
The warning signs
  • Slow and jumpy growing slower than its size class, with revenue that swings more

Boat condition = number of warning signs: a serious warning filing in 12 months; liabilities over assets; slow and jumpy; negative operating cash; an operating loss; negative free cash flow outside regulated utilities; an 80% revenue range of ±25% or wider. A picture of the signs, not a rating and not investment advice.

Brand success factors · calendar 2025

The Trillion Score: 457

Exponential Success Score

Built on over $200 trillion of sworn revenue, 13 years of data, 770,002 figures. Sealed by Edgarette.

How The Trillion Score works. We read eight measures of success from Quest Diagnostics's own SEC filings and test each one against the public companies in its field, here medical laboratories. The longer and fuller the record, the more weight those results carry. A model built on past filings then turns them into the odds of thriving, which means outgrowing the field for three years without a severe decline. A score of 500 is about average, and every 100 points doubles the odds. Every company is ranked on this same scale.

What it says here. At 457, Quest Diagnostics's odds of thriving come to 30%, against about 37% for the typical filer. It meets 2 of 8 success points.

457The Trillion Score
30%modeled odds of thriving over three years
MediumFall Risk
#11 of 16rank in its field
#2,016 of 2,824rank across all filers

What the score means

The higher the score, the more often companies went on to thrive. At this level, about 35 of every 100 did.

31%Under 45035%450 to 499This company: 45738%500 to 54944%550 to 59957%600 and up

Share of companies that beat their field for three years with no severe decline, tested on 2019 to 2022 filings.

Fall Risk: Medium

Separate from the score, this asks what could go wrong: the odds of sales falling 30% or the filings stopping within three years. In the tests, about 22 of every 100 companies in the Medium band did. That is the group's history, not a forecast for this company.

MoneyIt keeps about 12 cents of free cash from each sales dollar after paying for its plants and equipment. Debt after cash comes to about 43 cents for each dollar of yearly sales.low
SwingsIn its worst fifth of years, sales fell about 9% a year.-8.8% a year
Filed eventsIn the last two years it told the SEC about 1 filings on leadership or auditor changes.1

The eight success points

PointWhat it meansPlace in field
SpeedSales grew slower than much of its field.24 of 100Not yet
SteadinessGrowth swung a lot for what it delivered.44 of 100Not yet
Price premiumIt keeps less of each sales dollar than the leaders in its field.27 of 100Not yet
Margin stays above the fieldIts margin has not held above the field for long.33 of 100Not yet
Moat half-lifeIts margin edge is fading fast, or it has none yet.25 of 100Not yet
Brand spend yieldBrand spending returns more gross profit than for most of its field.64 of 100Met
Learning curveCosts fell as a share of sales as it grew.67 of 100Met
Climb in the fieldIt has not been moving up the size ranks in its field.44 of 100Not yet

The actuarial view

CredibilityWith 8 years of filings, the record earns 70% of the weight. The rest stays at the middle of the field.0.70
Severe decline, class CAbout 30 of every 100 companies with this many points fell 30% or stopped reporting within three years.30.1%
Actual vs expectedSales are 22% lower than if it had simply kept pace with its field.0.78

Top of its field: #1 Veracyte · #2 Castle Biosciences · #3 Guardant Health · #4 Exact Sciences · #5 Natera

Ranked by The Trillion Score. See the method and score your own brand. Tested on 2019 to 2022 filings. Odds, class and Fall Risk figures are the experience of similar filers, not a forecast for this company. A statistical description of past filings, not a rating or advice.

Recent filings
Measured, not prophesiedSuccess tools: score it, compare it, see its fieldFour questions. Scored against the SEC filings of the companies in your field.

Try InstagramSpriteHokaDisneyGatoradee.l.f.

Each benchmark is the median of SEC filers in your industry code, from their own audited filings, read on the filing boards. Reporting, not investment advice.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price. Reporting, not investment advice. No price targets and no trading recommendations. Figures from the SEC’s own data · every filing · this page as JSON · Open in Excel (CSV) · Ten-year table (CSV) ·

1 · Follow

Follow their filings

Or tap watch on any row above. You get the company’s live filing feed and Edgar’s card. Nothing to sign up for.

On Bluesky: follow Edgar & Edgarette.

2 · Price it

A new leader’s rebrand and launch

Priced live by the same engine as our estimator, from the catalogue at wholesale.

Price the printing · Open the full estimator

✦ Build the kit yourself
3 · Confirm

Check it with Jenny

Most buyers check what they found, or what their AI found, with one person before they commit. That person is the principal.

Jenny Huang Goodman MPA MSc MHSA, Principal

Book a time info@pops4.com
Independence. Every range, flag and score on these boards is identical for everyone. Clients of POPS4 or Hako Shikin receive no different numbers, no earlier access and no say in what is published. The service lines shown beside each board describe work we do; they never change the data. For reviewers: Method · Terms of use · Status
Free · unsponsored · source-linked

Clean data. No ads. Not now, not later.

Nine boards reading every SEC filing the business day after it lands, from the settled SEC daily index, ten editorial desks publishing daily, an open endpoint other AIs can query, and a 70,000-product house behind all of it. This is the public record end of it.

Every row is a filing.Straight from the company's own SEC document, linked. Nothing written, nothing inferred.
Nobody is watching you read.No ad trackers, no cookies from us. Our page counts are cookieless.
One email, one job.Watch a company and we hold that address for the alert alone. One tap ends it. Never shared, never passed on.
The house pays for this.Corporate event programs, corporate supplies and branded merchandise, since 1997. That is what funds the desks, under the house's own vendor standards.
Free to reuse with credit · CC BY 4.0 · how the boards are built
Data & Disclosure Notice: Edgar and Edgarette are automated software. Every figure on this page is calculated by software from public filings made by companies and funds with the U.S. Securities and Exchange Commission (EDGAR) and is published without individual human review. The accuracy and completeness of those filings are the responsibility of the filers; reports can contain errors and can be amended. Figures are shown as filed and as of each filing's date, and this page may be corrected or updated without notice. Ranges, expected returns, rankings, boats and other measures are statistical descriptions of past filings, not ratings, price forecasts, company guidance or recommendations; past results do not guarantee future results. This is general information published for all readers, not advice tailored to any person's portfolio, needs or circumstances, and nothing here is financial, investment, actuarial, legal, tax or other professional advice. Actuaries and other professionals who use these figures remain responsible for reviewing them for reasonableness and consistency against the original filings and for disclosing their reliance on them. No company, fund or reinsurer pays to be included or ranked. Provided as is, without warranty of any kind. Not affiliated with or endorsed by the SEC or by any company, fund or reinsurer named. All trademarks remain the property of their owners.